文献速递类风湿关节炎

利妥昔单抗对类风湿关节炎患者淋巴结活检中T和B细胞亚群的影响

Effect of rituximab treatment on T and B cell subsets in lymph node biopsies of patients with rheumatoid arthritis.
PubMed 文献 · Rheumatology (Oxford) · 2019-01-01

结果显示利妥昔单抗治疗后淋巴结B细胞未被完全清除,CD27+IgD-类别转换记忆B细胞持续存在,早期活化组织驻留T细胞显著减少但晚期活化T细胞持续存在,IL-21表达不受利妥昔单抗影响。结论提示利妥昔单抗不能治愈RA,可能与淋巴结中类别转换记忆B细胞持续存在有关。

要点

  • 利妥昔单抗治疗后淋巴结B细胞未被完全清除,类别转换记忆B细胞持续存在。
  • 治疗后淋巴结 naïve B细胞、非类别转换记忆B细胞及滤泡B细胞显著减少。
  • 早期活化组织驻留T细胞显著减少,但晚期活化T细胞持续存在。

核心结论

  • 利妥昔单抗不能治愈RA,可能与淋巴结中类别转换记忆B细胞持续存在有关,提示需额外靶向促进B细胞存活和分化的因素。

研究设计与样本

  • 组织采用流式细胞术、免疫组化和定量PCR检测。

主要发现

  • 与健康对照相比,RA患者淋巴结活检中CD21+CD23+IgDhighIgMvariable滤泡B细胞和CD3+CD25+CD69+早期活化组织驻留T细胞频率增加。
  • 利妥昔单抗治疗后淋巴结B细胞不完全清除,CD27-IgD+ naïve B细胞、CD27+IgD+非类别转换记忆B细胞(包括CD27+IgD+IgM+亚群)及滤泡B细胞显著减少。
  • 利妥昔单抗治疗后淋巴结活检中CD27+IgD-类别转换记忆B细胞持续存在。
  • 利妥昔单抗治疗后早期活化组织驻留T细胞频率显著减少,但晚期活化T细胞持续存在。
  • 促B细胞增殖细胞因子IL-21在RA患者淋巴结活检中表达高于健康对照,且利妥昔单抗治疗不影响其表达。

临床怎么用

  • 利妥昔单抗治疗RA时需关注淋巴结中类别转换记忆B细胞持续存在,提示可能需要联合靶向B细胞存活和分化相关因素的策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The exact underlying mechanism of rituximab treatment in patients with RA is poorly defined and knowledge about the effect of B cell depletion on immune cells in secondary lymphoid organs is lacking. We analysed lymphoid tissue responses to rituximab in RA patients. METHODS: Fourteen RA patients received 2 × 1000 mg rituximab intravenously, and lymph node (LN) biopsies were obtained before and 4 weeks after the first infusion. Tissues were examined by flow cytometry, immunohistochemistry and quantitative PCR. LN biopsies from five healthy individuals (HC) served as controls. RESULTS: LN biopsies of RA patients showed increased frequencies of CD21+CD23+IgDhighIgMvariable follicular B cells and CD3+CD25+CD69+ early activated, tissue resident T cells when compared with HCs. After treatment, there was incomplete depletion of LN B cells. There was a significant decrease in CD27-IgD+ naïve B cells, and CD27+IgD+ unswitched memory B cells including the CD27+IgD+IgM+ subset and follicular B cells. Strikingly, CD27+IgD- switched memory B cells persisted in LN biopsies after rituximab treatment. In the T cell compartment, a significant decrease was observed in the frequency of early activated, tissue resident T cells after rituximab treatment, but late activated T cells persisted. B cell proliferation inducing cytokine IL-21 was higher expressed in LN biopsies of RA patients compared with HC and expression was not affected by rituximab treatment. CONCLUSION: Rituximab does not cure RA, possibly due to persistence of switched memory B cells in lymphoid tissues suggesting that factors promoting B cell survival and differentiation need to be additionally targeted.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Ramwadhdoebe TH, van Baarsen LGM, Boumans MJH, et al. Effect of rituximab treatment on T and B cell subsets in lymph node biopsies of patients with rheumatoid arthritis. Rheumatology (Oxford). 2019. PMID: 30649469. doi:10.1093/rheumatology/key428

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。